SurModics, Inc.
http://www.surmodics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From SurModics, Inc.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet
Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate
Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.
SurModics Resumes TRANSCEND Trial Of SurVeil Drug-Coated Balloon
SurModics suspended the trial with their SurVeil drug-coated balloon in March after the US FDA sent a letter to physicians alerting them to possible safety problem with paclitaxel-coated devices. The company has updated the patient consent form and established a new patient follow-up program for the trial.
SurModics Recruits Abbott To Commercialize SurVeil Drug-Coated Balloon
Abbott will pay SurModics $25m upfront and up to $67m in milestones for the exclusive right to commercialization SurVeil worldwide.
Company Information
- Industry
- Distributors
- Medical Devices
-
In Vitro Diagnostics
- Chemistry, Immunoassay
- Other Names / Subsidiaries
-
- Brookwood Pharmaceuticals, Inc.
- BioFX Laboratories, Inc.
- Creagh Medical Ltd.
- Embolitech Inc
- NorMedix, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice